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Introduction
A malignant neoplasm may be associated with a host of poten-
tial complications. Haematogenous metastases may cause
spinal cord compression,1–4 pathological fractures,1,3,4 hyper-
calcaemia,3,5 pleural effusion,5–7 and pericardial tampon-
ade.5,6,8,9 Some complications, however, are due to the sys-
temic effects of a tumour. These conditions include deep vein
thrombosis (DVT),5 hypoglycaemia,10,11 and the syndrome of
inappropriate antidiuretic hormone.5,12,13
The association of DVT and malignancy was first reported
by Trousseau in 1865.14 The presence of malignancy places the
patient at a very high risk of DVT after major surgery, includ-
ing operations where there is no residual tumour. The re-
ported prevalence is 40% to 80% for calf vein thrombosis and
10% to 20% for proximal vein thrombosis, compared with
prevalences of 10% to 20% and 2% to 4%, respectively, in pa-
tients without malignancy.15
Deep Vein Thrombosis and Malignancy: A Surgical
Oncologist’s Perspective
Both DVT and its potentially fatal sequel, pulmonary
embolism, may have symptoms and signs that are either ab-
sent or non-specific.16,17 In fact, the first clinical manifestation
of DVT may be a fatal pulmonary embolism. Iliofemoral
thrombosis may present with phlegmasia caerulea dolens.
This becomes limb- and life-threatening when the massive
limb swelling is associated with arterial thrombosis.18 Post-
phlebitic syndrome is a state of chronic venous insufficiency
due to loss of venous valvular function during reorganization
of the thrombus.19
The most important goal of prophylaxis for venous throm-
boembolism is to prevent fatal pulmonary embolism. Through
the proper identification of the oncology patient at risk and
estimation of the magnitude of this risk, a prophylaxis regi-
men can be tailored to provide the desired risk reduction with
minimal adverse effects.
This review is based on a MEDLINE search of English-
language medical literature. Emphasis was placed on random-
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ized controlled trials and studies involving patients with
malignancies.
Reasons why DVT is more common in
presentation with malignancy
The causes of thrombosis are a triad of stasis of blood, altera-
tion in the composition of blood and changes in the vessel wall
(Virchow’s triad).20,21
The pathogenetic mechanisms of venous thrombosis when
there is an underlying malignancy are multiple. Thrombocy-
tosis has a known association with cancer.22 Tumours pro-
duce thrombin,23,24 which aids in tumour cell adhesion, and
tissue factor, which is a potent coagulant.25 Increased levels of
factor VIII and fibrinogen are also present.26 These act in
concert to increase the thrombogenic potential in the cancer
patient.
The tumour may compress adjacent vessels, resulting in
blood stasis, as is seen with pelvic tumours compressing the
iliac veins. When invading tumour cells invade and breach the
endothelium of vessels, the coagulation cascade is triggered
by the exposed collagen.27
In addition, the patient may have other risk factors for
DVT unrelated to the malignancy, such as trauma, heart
failure, increased age, immobility, pregnancy, thrombophilia
from inherited defects or the presence of antiphospholipid
antibodies.28,29 These risk factors are additive, with the risk of
venous thromboembolism increasing as the number of con-
current risks increases.30
Drugs used in cancer therapy may also contribute to the
risk of thrombosis. Tamoxifen, a selective oestrogen receptor
modulator that is used in hormonal therapy for breast cancer,
has been associated with thromboembolism; when used in
metastatic breast cancer, 3% of patients were reported to
develop venous thrombosis.31 However, there was no placebo
control group in this report. The risk is further increased with
concurrent chemotherapy in breast cancer patients. A ran-
domized trial in postmenopausal breast cancer patients with
node-positive disease in the absence of distant metastases
found that 13.6% of those who were given tamoxifen plus
chemotherapy (cyclophosphamide, methotrexate, fluo-
rouracil) developed thromboembolic events compared
with 2.6% who only received tamoxifen (p < 0.0001).32 Data
from seven Eastern Cooperative Oncology Group trials were
pooled and showed a significant difference in venous throm-
bosis rates between postmenopausal breast cancer patients
given chemotherapy (various regimens) with tamoxifen and
those given tamoxifen alone (8.0% vs 2.3%; p = 0.03).33 Chemo-
therapy itself has been shown to independently contribute to
thrombosis.34 Radiotherapy is also associated with DVT when
used to treat gynaecological malignancies35 and lymphoma.36
Certain cancers are associated with a higher incidence of
DVT. Using the standardized incidence ratio as a measure of
relative frequency, these are malignancies of the pancreas,
ovary, liver (primary), brain, lymphoid tissue and bone mar-
row (polycythaemia vera) (Table 1).37,38 However, because the
incidences of prostate and primary lung cancer are high, these
cancers are the most frequently encountered among DVT
patients.37–39 The frequency with which malignant cells are
found in distant thromboses is difficult to determine. An
autopsy study of eight cases of pancreatic cancer with multiple
venous thromboses distant from the tumour site found tu-
mour cells in the veins of the lower limb in only one case.40
Incidence of DVT in Asians
The incidence of DVT in Asians is believed to be lower than that
in Caucasians. This is supported by studies of incidence rates
in Asian countries41,42 as well as Asian minorities in Western
countries.43,44 A report from California quoted an age- and sex-
standardized incidence risk ratio of 0.26 for idiopathic DVT
and a relative risk of recurrent DVT of 0.65 among Asians or
Pacific Islanders relative to Caucasians.44 However, other stud-
ies have reported rates similar to Western populations.45,46
The role of routine thromboprophylaxis in Asian patients
is still being defined. Routine prophylaxis is probably indi-
cated in selected cases, such as major surgery.45,47 A randomized
controlled trial found that prophylaxis with enoxaparin for
major colon and rectal surgery in Asian patients led to a re-
duction in the rate of DVT (p = 0.045);48 94% of the patients
studied had cancer.
Table 1. Malignancies commonly associated with deep vein
thrombosis
Tumour37,38 Standardized incidence ratio
Pancreas 6.0, 7.8
Ovary 5.2, 11.4
Liver (primary) 3.2, 6.6
Brain 3.0, 7.6
Hodgkin’s lymphoma 7.4
Non-Hodgkin’s lymphoma 2.9, 4.2
Polycythaemia vera 12.9
Standardized incidence ratio = ratio of observed to expected number
of cases for particular cancer.
ASIAN JOURNAL OF SURGERY  VOL 27 • NO 3 • JULY 2004 251
070/2001
■ DEEP VEIN THROMBOSIS IN CANCER ■
Occult cancer in idiopathic DVT
Some studies report a 2% to 25% incidence of patients with
idiopathic DVT subsequently diagnosed with malignan-
cies.49,50 This has led to the debate as to whether all cases pre-
senting with DVT should be screened for the presence of
malignancy.
There are few, if any, reports of unsuspected malignancy
diagnosed after idiopathic DVT among Asian patients. Thus,
the issue of whether to screen for malignancy in Asian patients
cannot be adequately answered with current data. In the lit-
erature, the general consensus is that extensive cancer screen-
ing is not justifiable.37,49,51 An evaluation consisting of a thor-
ough history and physical examination with routine blood
tests and chest radiograph would suffice.
Management of DVT
In the patient who is known to have cancer, there must be a
high index of suspicion for the presence of DVT and pulmo-
nary embolism. This is especially important in patients with
unresected tumours, advanced disease, or those undergoing
chemotherapy and/or radiotherapy, where the presence of
tumour tissue is an ongoing stimulus for the thrombotic
process.
The routine treatment of DVT involves the use of intrave-
nous unfractionated heparin infusion which is then replaced
by an oral anticoagulant after at least 5 days of overlapping
drug administration.26,52 Low-molecular-weight heparin
(LMWH) is replacing unfractionated heparin for the treat-
ment of DVT.53 Oral anticoagulants should be given for as
long as the cancer remains active.26,54 However, administering
medication orally may be difficult if these patients have ano-
rexia and vomiting.55 In this scenario, LMWH has advantages
of parenteral dosing without the need for frequent laboratory
monitoring, and can thus be administered on an outpatient
basis. Dosing regimens may need adjustment according to
the different average body weight of Asians.56 In the treatment
of thrombosis in cancer patients, bleeding may be a serious
problem. This may occur at the site of the primary tumour,
metastatic deposits or recent surgical wounds. When the risk
of serious bleeding is high, vena cava interruption with a
Greenfield filter should be employed instead of the standard
treatment with heparin.26
Recurrent venous thrombosis occurs more frequently in
patients with cancer.26 It has been suggested that all cancer
patients with DVT should have a vena cava filter placed to
prevent pulmonary embolism. A randomized controlled trial
in patients with DVT, regardless of aetiology, showed that
although the filter group had a lower incidence of pulmonary
embolism at 2 years (3.4% vs 6.3%; p = 0.16), this was offset by
a significantly higher incidence of recurrent DVT in the filter
group (20.8% vs 11.6%; p = 0.02).57 Another study found that
17% of patients with filters developed major recurrent throm-
boembolic complications on retrospective review.58 Hence,
the use of vena cava filters is not without risk and should be
restricted to patients with specific contraindications to
anticoagulation.
A further issue is whether patients with advanced can-
cer and DVT should be treated. Treatment would help
to alleviate the local symptoms of leg swelling and pain, as
well as dyspnoea and chest pain when pulmonary embolism
is present.59 On the other hand, the patient’s life expec-
tancy and quality of life may be so poor as not to warrant
any therapy that has associated adverse effects, especially
bleeding.60 The decision would have to be based on a weigh-
ing of these factors, in addition to the patient’s and family’s
preferences.
Antineoplastic effects of heparin
Consistent with coagulation being important for tumour
growth and metastasis, the use of heparin in cancer has
been shown to significantly improve the survival of cancer
patients. In a randomized controlled trial in patients with
small cell lung cancer without thromboembolic disease,
Lebeau et al61 showed a significant improvement in survival
with prophylactic subcutaneous heparin compared with no
heparin, both in the overall group and in the subgroup with
limited disease. Patients who received heparin had overall
1-, 2- and 3-year survival rates of 40%, 11% and 9%, respective-
ly, compared to 30%, 9% and 6%, respectively, in the control
group.
The antineoplastic actions of heparin are multimodal and
include the inhibition of microthrombi formation, inhibition
of angiogenesis, reduction in tumour cell adhesion and block-
ade of a host of other organic chemicals involved in tumour
growth and metastasis.62
When LMWH was compared with standard intravenous
heparin in treating DVT, there was a significant reduction
in cancer-related mortality with LMWH.53,63,64 Further stud-
ies are required to investigate if this reduction in cancer-
related mortality persists with the use of LMWH in DVT
prophylaxis.65
252 ASIAN JOURNAL OF SURGERY  VOL 27 • NO 3 • JULY 2004
070/20
■ YAP AND McCREADY ■
Prophylaxis
Routine prophylactic measures against thromboembolism
should be used in cancer patients. A patient older than 40 years
with malignancy who is undergoing major surgery is consid-
ered to have a very high risk of thromboembolism.15,29 In such
a high-risk patient, the combined use of elastic compression
stockings, intermittent pneumatic leg compression and anti-
coagulant is indicated. Either low-dose heparin or LMWH is
appropriate, although LMWH has been shown to cause fewer
bleeding complications compared to unfractionated hepa-
rin.53,66,67 On the other hand, the indications for prophylaxis
in less extensive operations such as mastectomy are not clearly
defined in the literature. A reasonable approach would be to
use elastic compression stockings with early postoperative
ambulation.
Prophylaxis should also be considered for patients under-
going chemotherapy. Warfarin 1 mg/day is safe and effective
in stage IV breast cancer patients on chemotherapy.68 Caution
is necessary as drug interactions may potentiate the antico-
agulant property of warfarin and result in bleeding.69 As for
the routine use of thromboprophylaxis in cancer patients not
undergoing surgery or chemotherapy, there is currently insuf-
ficient evidence to support such a measure. Table 2 is a pro-
posed prophylaxis protocol for surgical oncology patients.
Conclusion
DVT in the cancer patient is a special entity. The pathogenesis
is unique and thrombosis itself is a feature of tumour growth
and metastasis. The frequency with which DVT occurs in
malignancy mandates a high index of suspicion when manag-
ing cancer patients. To reduce the incidence of DVT associated
with surgery, routine prophylaxis is recommended according
to the level of thrombosis risk. Patients undergoing chemo-
therapy or with advanced cancer may be given long-term
anticoagulation where not contraindicated.
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